scholarly journals From TTP to Glomerulonephritis: A Lifetime of Lupus

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Fadi Kharouf ◽  
Sigal Shahar ◽  
Yoav Hershkovitz ◽  
Alaa Shaheen ◽  
Areej Bayatra ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Deep Vein Thrombosis ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Disease Course ◽  
Systemic Lupus ◽  
Thrombocytopenic Purpura ◽  
Vein Thrombosis ◽  
Deep Vein ◽  
Excellent Clinical Outcome

We report the case of a 56-year-old male patient, who over two decades, sequentially presented with a combination of clinical manifestations. These included thrombotic thrombocytopenic purpura (TTP), right leg deep vein thrombosis (DVT), and eventually constitutional symptoms, arthralgia, diffuse lymphadenopathy, pancytopenia, skin rash, pericarditis, and glomerulonephritis. Serologic tests and renal pathology uncovered a diagnosis of systemic lupus erythematosus (SLE), and immunosuppressive therapy was initiated. Soon after, the patient developed striking cytomegalovirus (CMV) viremia, requiring prolonged antiviral therapy and reduction of immunosuppression. Finally, an acute embolic stroke complicated the disease course. Prompt interventions allowed an excellent clinical outcome.

Recurrent antiphospholipid-related deep vein thrombosis as presenting manifestation of systemic lupus erythematosus

2000 ◽  
Vol 159 (3) ◽  
pp. 211-214 ◽  
Author(s):  
Marco Gattorno ◽  
Angelo Claudio Molinari ◽  
Antonella Buoncompagni ◽  
Maura Acquila ◽  
Stefano Amato ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Deep Vein Thrombosis ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Vein Thrombosis ◽  
Deep Vein

Profiling of non-criteria antiphospholipid antibodies in patients with SLE: differentiation of thrombotic SLE patients and risk of recurrence of thrombosis

Lupus ◽  
2020 ◽  
Vol 29 (5) ◽  
pp. 490-498
Author(s):  
O Tkachenko ◽  
S Lapin ◽  
A Mazing ◽  
V Emanuel ◽  
E Belolipetskaia ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Deep Vein Thrombosis ◽  
Confidence Interval ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Odds Ratio ◽  
Arterial Thrombosis ◽  
Systemic Lupus ◽  
Vein Thrombosis ◽  
Deep Vein

To reveal the clinical significance of criteria and non-criteria antiphospholipid antibodies detected by line immunoassay in comparison with ELISA, systemic lupus erythematosus patients with and without thrombotic events were investigated. Thus, 107 systemic lupus erythematosus patients (48% with deep vein thrombosis or/and arterial thrombosis) and 120 healthy donors were enrolled. Serum antiphospholipid antibodies were detected by ELISA (Orgentec Diagnostika, Germany) and line immunoassay (GA Generic Assays, Germany). Lupus anticoagulant and IgG to cardiolipin and β2GPI but not IgM as well as triple positivity by ELISA and line immunoassay were linked with thrombosis in systemic lupus erythematosus. IgG to phosphatidylinositol and phosphatidylserine by line immunoassay showed significantly higher levels in systemic lupus erythematosus with deep vein thrombosis/arterial thrombosis than without and were independent risk factors for deep vein thrombosis (odds ratio 3.9, 95% confidence interval 1.1, 13.2) and arterial thrombosis (odds ratio 5.1, 95% confidence interval 1.3, 19.8) as well as thrombosis (odds ratio 3.6, 95% confidence interval 1.1, 11.3) and recurrence thereof (odds ratio 6.9, 95% confidence interval 2.1, 22.6), respectively. The occurrence of >4 IgG antiphospholipid antibodies by line immunoassay was an independent risk factor for thrombosis (odds ratio 10.9, 95% confidence interval 1.2, 101.5), arterial thrombosis (odds ratio 14.6, 95% confidence interval 2.5, 86.3), deep vein thrombosis (odds ratio 5.8, 95% confidence interval 1.0, 32.4) and recurrence of thrombosis (odds ratio 35.9, 95% confidence interval 3.8, 342.8). Line immunoassay is a promising multiplex test for the simultaneous detection of criteria and non-criteria antiphospholipid antibodies. Profiling of antiphospholipid antibodies by line immunoassay can differentiate systemic lupus erythematosus patients with thrombosis from systemic lupus erythematosus patients without and assess the risk for thrombosis and recurrence thereof.

scholarly journals Primary Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) with Multiple Deep Vein Thrombosis- Case Report

2020 ◽  
Vol 8 (10) ◽  
pp. 882-885
Author(s):  
Dr. Krishna Kumar Dhakchinamoorthi ◽  
Dr. Ann Mary Alex ◽  
Dr. Nikhil Cherian Sam ◽  
Dr. Jeevanantham R ◽  
Mohamed Sulaiman G ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Deep Vein Thrombosis ◽  
Case Report ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Primary Antiphospholipid Syndrome ◽  
Systemic Lupus ◽  
Vein Thrombosis ◽  
Deep Vein

A significant improvement of thromboses treated by a new oral anticoagulant in an 11-year-old girl with systemic lupus erythematosus associated antiphospholipid syndrome: A case report

Lupus ◽  
2021 ◽  
pp. 096120332110160
Author(s):  
Yen-Jung Chiang ◽  
Ya-Chiao Hu ◽  
Bor-Luen Chiang
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Deep Vein Thrombosis ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Oral Anticoagulants ◽  
Close Monitoring ◽  
Systemic Lupus ◽  
Vein Thrombosis ◽  
New Oral Anticoagulant ◽  
Deep Vein

Pediatric venous thrombosis is associated with a variety of chronic diseases. Antiphospholipid syndrome (APS) is one of them and is commonly related to systemic lupus erythematosus (SLE). Warfarin is the mainstream of anticoagulation treatment in pediatric APS currently but it needs close monitoring and frequent dose adjustment. New oral anticoagulants (NOAC) is one of the innovative options in recent years but there is a lack of report in secondary prevention of deep vein thrombosis (DVT), especially pediatric APS. Herein we reported the significant therapeutic effect of edoxaban in a 11-year-old girl of newly diagnosed SLE and APS, who had deep vein thrombosis as the initial presentation.

scholarly journals Monophasic Disease Course in Systemic Lupus Erythematosus

2018 ◽  
Vol 45 (8) ◽  
pp. 1131-1135 ◽  
Author(s):  
Konstantinos Tselios ◽  
Dafna D. Gladman ◽  
Zahi Touma ◽  
Jiandong Su ◽  
Nicole Anderson ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Clinical Manifestations ◽  
Central Nervous System Involvement ◽  
Time Interval ◽  
Sustained Remission ◽  
Disease Course ◽  
Systemic Lupus ◽  
Number Of Patients

Objective.Disease course in systemic lupus erythematosus (SLE) is primarily relapsing-remitting. Long quiescent and chronically active patterns are less frequent. We recently described an atypical “monophasic” course in a small number of patients. The aim of the present study was to assess the prevalence and characteristics of such patients in a defined SLE cohort.Methods.The inception patients of the University of Toronto Lupus Clinic (enrolled within 18 mos of diagnosis) were investigated. No time interval > 18 months was allowed between consecutive visits. A monophasic course was defined as Systemic Lupus Erythematosus Disease Activity Index 2000 = 0 (serology excluded), achieved within 5 years since enrollment and maintained for ≥ 10 years. Descriptive statistics were used.Results.Of 267 inception patients, 27 (10.1%) achieved prolonged clinical remission (≥ 10 yrs) and 20 (7.5%) sustained remission for the entire followup (18 yrs on average). Twelve patients were receiving no maintenance treatment 10 years after achieving remission. Clinical manifestations at diagnosis (apart from skin and musculoskeletal involvement) included 25% in each of central nervous system involvement and lupus nephritis (LN). Half the patients were serologically active. Ten years after achieving remission, two-thirds of the patients had discontinued glucocorticosteroids; the remaining were treated with 5 mg/day on average. Seven patients relapsed after 10 years, 4 with arthritis, 2 LN, and 1 catastrophic antiphospholipid syndrome.Conclusion.A monophasic disease course was observed in 7.5% in this inception cohort. Patients sustained remission for 18 years on average, eventually without medications. Further study of such patients may provide unique pathophysiologic insights for SLE.

Sign in / Sign up

Export Citation Format

Share Document